New drug aims to tame Crohn's Flare-Ups for years
NCT ID NCT07184944
Summary
This large, late-stage study is testing whether an investigational drug called duvakitug can help people with moderate to severe Crohn's disease stay in remission and reduce intestinal inflammation over the long term. About 671 participants who responded to the drug in a prior study will receive either duvakitug or a placebo for 40 weeks, with an option to continue for up to 5 more years. The main goals are to see if the drug keeps symptoms like pain and diarrhea low and improves gut healing seen on a scope.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Research of Osceola-Site Number: 8400013
RECRUITINGKissimmee, Florida, 34741, United States
-
Tyler Research Institute LLC-Site Number: 8400095
RECRUITINGTyler, Texas, 75701, United States
Conditions
Explore the condition pages connected to this study.